fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Health Canada approves Darzalex + bortezomib + cyclophosphamide + dexamethasone to treat light chain amyloidosis – Janssen Biotech

Written by | 9 May 2021

Health Canada has approved daratumumab injection (Darzalex SC), a subcutaneous formulation of daratumumab (Darzalex), for use in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd; VCd) in the treatment… read more.

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes – AstraZeneca

Written by | 3 May 2021

AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.

Protected: FDA grants accelerated approval for Jemperli in endometrial cancer – GSK

Written by | 1 May 2021

There is no excerpt because this is a protected post.

Cycling study transforms heart health of dialysis patients

Written by | 18 Apr 2021

Cycling at moderate intensity during dialysis could drastically improve the heart health of patients with kidney failure and result in significant savings for the NHS, according to new… read more.

FibroGen provides additional information on roxadustat to the FDA relating to U.S. primary cardiovascular safety analyses

Written by | 17 Apr 2021

FibroGen, Inc. has provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase III program for the treatment of anemia of chronic… read more.

Link between lactation and visceral, pericardial fat

Written by | 15 Apr 2021

As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don’t or… read more.

GW Pharmaceuticals receives positive CHMP opinion for Epidyolex for use as treatment of seizures associated with tuberous sclerosis complex

Written by | 14 Mar 2021

GW Pharmaceuticals plc , a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for… read more.

The FDA will convene an Advisory Committee meeting to review the NDA for roxadustat to treat anemia of CKD – AstraZeneca + FIbroGen Inc

Written by | 7 Mar 2021

AstraZeneca and FibroGen, Inc. announced that the FDA informed FibroGen that it will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the new… read more.

New class of drug leads to 30% reduced risk of death for bladder cancer patients

Written by | 27 Feb 2021

A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of… read more.

Cabozantinib most effective treatment for metastatic papillary kidney cancer

Written by | 25 Feb 2021

In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with… read more.

Targeted drug combination improves survival in advanced kidney cancer

Written by | 24 Feb 2021

Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer. The combination also improved progression-free survival… read more.

Why COVID-19 pneumonia lasts longer, causes more damage than typical pneumonia

Written by | 24 Jan 2021

Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung over the course of hours.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.